Liminatus Pharma (NASDAQ:LIMN – Get Free Report) and Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends. Earnings and Valuation This table compares Liminatus […]

Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) and Liminatus Pharma (NASDAQ:LIMN – Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Insider & Institutional Ownership 3.8% of Inhibikase […]